On Sept. 14, FDA approved updated labeling for Temodar (temozolomide) under Project Renewal, an Oncology Center of Excellence initiative aimed at updating labeling information for older oncology drugs to ensure information is clinically meaningful and scientifically up-to-date.
Scientific progress often follows a prolonged path, but bioentrepreneur Samy Lamouille believes his dedication toward this pursuit will ultimately pay off for brain cancer patients.
